Leading boba brand to open stores in Kuala Lumpur and Phnom Penh, as it focuses on further diversifying beverages tailored to local tastes
KUALA LUMPUR, Malaysia and PHNOM PENH, Cambodia, April 30, 2025 /PRNewswire/ -- Leading tapioca tea brand CoCo Bubble Tea is announcing new store openings in Malaysia and Cambodia later this spring. Along with the new locations, CoCo will seek to further customize and cater to varied local tastes to meet growing demand for diversified refreshments.
To explore opening a pearl milk tea shop with CoCo Bubble Tea, please visit: https://bit.ly/3OFKWWC
In May, CoCo will open the first store in a multi-store franchise in Kuala Lumpur, Malaysia, with the remaining locations opening later in 2025. These stores will feature beverages made with raw materials certified as Halal, emphasizing the brand's dedication to making beverages for everyone to enjoy. Additionally, CoCo held the soft opening for its first-ever store in Cambodia, located in Phnom Penh, on April 13. This marks a significant step in bringing its beloved bubble tea to even more communities across Southeast Asia.
"Our franchise network from the dynamic Southeast Asia region does an excellent job innovating and harnessing the flourishing bubble tea market here," noted Kody Wong, Deputy General Manager of Business Development at CoCo Bubble Tea. "We are immensely grateful to have such strong franchise partners. With these latest openings, we are doubling down on our efforts to engage diverse consumers across a region that is growing rapidly."
Striving for broader local appeal
As demand for "new tea" drinks grows in Southeast Asia, CoCo is redefining the bubble tea experience in the region. Once considered a premium refreshment option, bubble tea is now evolving to suit the dynamic tastes of a broader range of Southeast Asian consumers. The brand's focus on using local flavors and offering customizable beverage options is helping its drinks resonate more with middle-class consumers, who have increasingly more purchasing power.
A history of success in Southeast Asia
Since establishing a presence here in 2012, Southeast Asia has brought CoCo Bubble Tea some outstanding success stories. Notably, the Philippines has over 120 CoCo stores nationwide, and the brand has consistent recognition here for beverages that resonate with consumers, a strong brand image, and outstanding customer service. CoCo's highest average store sales is in the Philippines, and it has been the most successful among locals compared with tourists — as 99% of its customers are Filipinos. This demonstrates the company's proven ability to connect deeply with local tastes.
Why partner with CoCo
Operating with a franchise business model, CoCo Bubble Tea is deeply invested in the entrepreneurs it partners with to open shops. With over 5000 stores worldwide, CoCo combines its high brand recognition with comprehensive support across supply chain, training programs, and other areas to ensure the long-term success of its franchise partners.
Looking ahead
As CoCo continues its expansion, the brand remains committed to introducing its customized and culturally inspired tea creations to more countries across Southeast Asia — and the world. With the increasing popularity of bubble tea in the region, the brand is poised to further strengthen its foothold and delight consumers with unique and refreshing beverage options.
About CoCo Bubble Tea
CoCo Bubble Tea aims to create a diverse and sustainable community for its consumers by providing visually refreshing products. We continue to be one of the fastest-growing companies and are looking for enterprising partners to join the CoCo Bubble Tea franchise networks. Check CoCo Bubble Tea's official website and start your application now.
For more information, please visit https://www.coco-tea.com/.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CoCo Bubble Tea Announces New Openings in Southeast Asia
CoCo Bubble Tea Announces New Openings in Southeast Asia
CoCo Bubble Tea Announces New Openings in Southeast Asia
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
